HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) A correction has been published All Versions of this Article: 34/1/200    most recent 09031936.00030908v1 Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Web of Science (1) Google Scholar Articles by Swedin, L. Articles by Dahlén, S-E. PubMed PubMed Citation Articles by Swedin, L. Articles by Dahlén, S-E.

Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice

¹ The National Institute of Environmental Medicine, Division of Physiology, Karolinska Institutet, ² Dept of Medicine Solna, Clinical Immunology and Allergy Unit, Karolinska Institutet and University Hospital, Stockholm, and ³ Dept of Medical Sciences, Clinical Physiology, Uppsala University, Uppsala, Sweden.

CORRESPONDENCE: L. Swedin, The National Institute of Environmental Medicine, Division of Physiology, Scheeles väg 1, Box 287, Karolinska Institutet, SE-171 77 Stockholm, Sweden. E-mail: linda.swedin{at}ki.se

Keywords: Airway hyperresponsiveness, allergic mouse model, cyclooxygenase inhibition, eosinophilic allergic reaction, prostaglandins

Received: February 28, 2008
Accepted February 9, 2009

The aim of the current study was to define how cyclooxygenase (COX)-activity affects airway hyperresponsiveness (AHR) and inflammation using interventions with COX inhibitors at different time points during allergen challenge and/or prior to measurement of AHR in an eosinophil-driven allergic mouse model. Inflammatory cells were assessed in bronchioalveolar lavage (BAL) and AHR was evaluated as the total lung resistance to methacholine (MCh) challenge.

Administration of FR122047 (COX-1 inhibitor) during ovalbumin (OVA) challenge and prior to MCh challenge enhanced AHR without affecting the inflammatory cell response. In contrast, administration of lumiracoxib (COX-2 inhibitor) during the same time period had no effect on AHR but reduced the inflammatory cells in BAL. Nonselective COX inhibition with diclofenac both enhanced the AHR and reduced the inflammatory cells.

Administration of diclofenac only during OVA challenge reduced the cells in BAL without any changes in AHR, whereas administration of diclofenac only prior to MCh challenge enhanced AHR but did not affect the cells in BAL.

The present study implicates distinct roles of prostanoids generated along the COX-1 and COX-2 pathways and, furthermore, that inflammatory cells in BAL do not change in parallel with AHR. These findings support the fact that AHR and the inflammatory response are distinct and, at least in part, uncoupled events.